
Oncora Medical has built a clinical decision support software that uses big data and sophisticated analytics to enable precision radiation oncology, which is the practice of designing personalized radiation treatments for each individual patient seen by a radiation oncology department. The company's offering includes:
Unity Unity integrates and organizes information from the existing treatment planning system, oncology information system, tumor registry, and EMR into a common high-performance database. The platform is vendor agnostic and can be customized to incorporate additional departmental data sources. Also, Unity has the ability to automatically curate clinical outcomes data using natural language processing and encounter level data from an EMR system. From there, it can determine (with confidence levels) which of the past patients suffered from on-treatment toxicities or experienced local or nodal failure. Finally, Oncora Medical lets its clients integrate with Unity through an API, that can be used both by in-house developers building custom applications and by advanced users wanting more direct access to the data Unity houses.
Focus Focus allows physicians, researchers, and administrators to create, store, and share custom viewpoints of departmental data. Viewpoints are interactive visualizations of a select set of variables on a subset of prior patients. Variables can be chosen from hundreds of predefined patient, treatment, and outcome fields; or users can create their own fields by combining others. Unlike "dashboards," which allow users to see data only from one perspective, viewpoints let users analyze their data from any angle. Focus includes an innovative tool that automatically generates insightful viewpoints based on the available data. This allows clinicians and researchers to more effectively explore their data and discover new trends.
Acumen Acumen lets providers calculate patient-specific toxicity risks, which is crucial for creating a personalized plan. Risk is determined by an advanced predictive model trained on past radiation treatments that combines the patient's physical attributes and medical history with details of the current cancer diagnosis to assess risk. The risk index is reported as a range of probabilities (such as 5% - 9%) that captures the uncertainties inherent in making outcome predictions while being easily interpretable as a probability of the adverse event occurring. Additionally, Acumen provides physicians with several treatment options, each of which shows suggested dose constraints alongside QUANTEC recommendations and institute averages. Finally, the solution can predict outcomes for proposed treatment plans.
Funding 💰
Total $2.6M
Select investors BioAdvance, iSeed Ventures, Dreamit Health, Dorm Room Fund
Last update: April 1, 2018